KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.

Meredith M Regan, Paolo A Ascierto, Evan J Lipson, Jennell Palaia, Andriy Moshyk, Abraham Selvan, Christopher D Lao, Michael B Atkins, David F McDermott, Ravi Potluri, Sandip Ranjan, Sandeep Bilthare, Georgina V Long, F Stephen Hodi, Hussein Tawbi, Dirk Schadendorf

J Immunother Cancer 13(9) e012747

PMID40940136
PMCIDPMC12519387
DOI10.1136/jitc-2025-012747
发表日期2025-09-12
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Treatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab. This analysis compared TFS for nivolumab plus relatlimab and nivolumab monotherapy in patients with advanced melanoma. METHODS: Data were from 714 patients in the phase 2/3 RELATIVITY-047 trial (ClinicalTrials.gov identifier: NCT03470922). TFS was defined as the difference in restricted mean event times between the Kaplan-Meier curves for time to protocol therapy cessation and time to subsequent systemic anticancer therapy initiation or death. TFS was further partitioned into time with and time without grade ≥3 treatment-related adverse events (TRAEs). Subgroup analysis based on tumor BRAF mutational status and tumor programmed death ligand 1 (PD-L1) expression level was conducted. Between-treatment group differences were calculated with bootstrapped 95% CIs. RESULTS: At 48 months from randomization, Kaplan-Meier estimates of overall survival were 52% and 43% for patients in the nivolumab plus relatlimab and nivolumab groups, respectively; 38% and 33% of patients in these respective groups were free of subsequent systemic therapy. The 48-month mean TFS was 2.9 months (95% CI 1.0 to 4.9) longer with nivolumab plus relatlimab than with nivolumab (9.7 vs 6.8 months, respectively). Mean TFS represented 20% and 14% of the 48-month period after initiating nivolumab plus relatlimab and nivolumab, respectively. Considering only time without grade ≥3 TRAEs, the 48-month mean TFS was 2.6 months (95% CI 0.8 to 4.5) longer with nivolumab plus relatlimab than with nivolumab (9.1 vs 6.5 months, respectively). The 48-month mean total TFS was consistently longer with nivolumab plus relatlimab than with nivolumab in the BRAF mutant (9.4 vs 6.5 months), BRAF wild-type (9.9 vs 6.9 months), PD-L1 ≥1% (12.3 vs 7.7 months), and PD-L1<1% (7.9 vs 6.2 months) subgroups. CONCLUSIONS: This analysis demonstrated TFS benefit during the 48 months since initiating nivolumab plus relatlimab compared with nivolumab alone in patients with advanced melanoma. A direct comparison between nivolumab plus relatlimab and nivolumab plus ipilimumab is needed to determine the differences between the regimens in TFS and those in traditional endpoints.

KM 提取结果

2 个 Figure · 7 个 KM 面板

进入结果中心
KM Figure5 个面板

Figure 1

Figure 1. Illustration of time to event endpoints. *Patients were censored if they were still on study drug at last follow-up visit, had withdrawn consent, or were still alive at end of study period. † Patients were censored if they were still on study drug, were off study drug and had not started subsequent systemic anticancer therapy at last follow-up visit, were lost to follow-up, or had withdrawn consent. ‡ Patients were censored if they were still on study drug at last follow-up visit or were at end of study period. TFS, treatment-free survival.

Overall_survival_E_

Overall survival

Figure 1 · Panel Overall_survival_E_

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Overall_survival_E_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Time_to_subsequent_therapy_initiation_or_death_C_

Time to subsequent therapy initiation or death

Figure 1 · Panel Time_to_subsequent_therapy_initiation_or_death_C_

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Time_to_subsequent_therapy_initiation_or_death_C_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Time_to_cessation_of_both_protocol_therapy_and_toxicity_B_

Time to cessation of both protocol therapy and toxicity

Figure 1 · Panel Time_to_cessation_of_both_protocol_therapy_and_toxicity_B_

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Time_to_cessation_of_both_protocol_therapy_and_toxicity_B_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Time_to_protocol_therapy_cessation_A_

Time to protocol therapy cessation

Figure 1 · Panel Time_to_protocol_therapy_cessation_A_

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Time_to_protocol_therapy_cessation_A_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Time_to_cessation_of_protocol_therapy_without_toxicity_D_

Time to cessation of protocol therapy without toxicity

Figure 1 · Panel Time_to_cessation_of_protocol_therapy_without_toxicity_D_

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Time_to_cessation_of_protocol_therapy_without_toxicity_D_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 2

Figure 2. Kaplan-Meier analyses of endpoints in all randomized patients by treatment group. Toxicity was defined as grade ≥3 TRAEs. Data labels represent RMST (months) in any health state and the percentage of time in the 48-month period. The Kaplan-Meier curves have been smoothed for better visualization. OS, overall survival; RMST, restricted mean event time; TFS, treatment-free survival; TRAE, treatment-related adverse event; TTD, time to discontinuation of study drug; TTS, time to subsequent systemic anticancer therapy initiation.

Nivolumab_plus_relatlimab

OS

Figure 2 · Panel Nivolumab_plus_relatlimab

quality_warning 待 EXE 对齐 预期 7 条 已提取 2 条

Panel Nivolumab_plus_relatlimab 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 7 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
Nivolumab

OS

Figure 2 · Panel Nivolumab

quality_warning 待 EXE 对齐 预期 7 条 已提取 4 条

Panel Nivolumab 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 7 条,实际恢复 4 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 3Figure 3. Differences in TFS, OS, and survival state mean times for nivolumab plus relatlimab versus nivolumab at 12, 24, 36, and 48 months of follow-up from randomization. OS, overall survival; TFS, treatment-free survival.
非 KM Figure